SAN

74.015

-0.34%↓

SRT3

226.8

+0.98%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.25

+4.7%↑

SAN

74.015

-0.34%↓

SRT3

226.8

+0.98%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.25

+4.7%↑

SAN

74.015

-0.34%↓

SRT3

226.8

+0.98%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.25

+4.7%↑

SAN

74.015

-0.34%↓

SRT3

226.8

+0.98%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.25

+4.7%↑

SAN

74.015

-0.34%↓

SRT3

226.8

+0.98%↑

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.25

+4.7%↑

Home・Akcijų sąrašas・Vetoquinol SA

Vetoquinol SA

Atidarymo kaina

SektoriusSveikatos priežiūra

77.1 1.31

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

76.5

Max

77.1

Pagrindiniai rodikliai
By Trading Economics
Pajamos	25M
Pardavimai	10M 268M
P/E Sektoriaus vid.	14.588 49.8
Dividendų pajamingumas	1.21
Pelno marža	9.734
Darbuotojai	2,497
EBITDA	252M 301M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+48.25% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.21% 2.25%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-57M 878M
Ankstesnė atidarymo kaina	75.79
Ankstesnė uždarymo kaina	77.1

Naujienos nuotaikos

By Acuity

36%

64%

136 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

72.6 / 75.1 Palaikymas ir pasipriešinimas

Vetoquinol SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-06 23:41; UTC

Uždarbis

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026-05-06 21:40; UTC

Uždarbis

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026-05-06 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-05-06 23:34; UTC

Rinkos pokalbiai

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026-05-06 23:12; UTC

Uždarbis

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026-05-06 23:11; UTC

Uždarbis

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026-05-06 23:07; UTC

Uždarbis

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026-05-06 23:05; UTC

Uždarbis

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026-05-06 23:04; UTC

Uždarbis

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-05-06 22:25; UTC

Rinkos pokalbiai

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026-05-06 22:05; UTC

Rinkos pokalbiai

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026-05-06 21:58; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:47; UTC

Rinkos pokalbiai

Uždarbis

Costco Posts 13% Sales Growth in April -- Market Talk

2026-05-06 21:46; UTC

Uždarbis

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026-05-06 21:40; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:35; UTC

Rinkos pokalbiai

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026-05-06 21:32; UTC

Karštos akcijos

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026-05-06 21:29; UTC

Uždarbis

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Vetoquinol SA Prognozė

Kainos tikslas

By TipRanks

48.25% į viršų

12 mėnesių prognozė

Vidutinis 110 EUR 48.25%

Aukščiausias 110 EUR

Žemiausias 110 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vetoquinol SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Vetoquinol SA akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

72.6 / 75.1Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

136 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.